Short Interest 26.22% Market Cap $1.28B Volume 47 Prev. Close $15.13 SNDX Analysis Syndax Looks Tantalizing, But Looks Can Be DeceptiveAvisol Capital PartnersTue, Jan. 211 Comment Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy OpportunityTerry ChrisomalisTue, Nov. 12, 20244 Comment...
SNDX | Complete Syndax Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Analyst Ratings typicall...